PATENT CLAIM ANALYSIS

Application Number: 15976225
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["514", "017700"]

Abstract:
The present disclosure provides compositions and methods for treating diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, for example, due to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.

Claim (Index 39):
The method of  claim 38 , wherein the biglycan polypeptide comprises an amino acid sequence which is at least 90% identical to SEQ ID NO: 9, or a fragment thereof.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 93.0
- Lexical Diversity: 1.55738
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13109558', '13996951', '12786294', '10486678', '10868247']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8519571655505171
- 35 USC 102 Novelty (BERT): 0.6910655242804592
- Combined Prediction Score: 0.8358680014235114
- Mean Citation Score: 674.5547960000001
- Max Citation Score: 775.4225
- Similarity Product: 675.2602046516538

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test